Boulder, Colorado. BiOptix Diagnostics, Inc., a Boulder, CO based analytical instrumentation firm, announced today the closing of $9M Series B financing. The $9M round was led by The Russian Corporation for Nanotechnologies (“RUSNANO”) which was joined in the round by Boulder Ventures Ltd., Peierls Foundation, and several private investors.

“RUSNANO has collaborated with high technology companies in the USA before, but this is the first time we have invested directly into an American legal entity. We are proud to be a part of such a great innovation story. I believe that products of BiOptix could open new horizons for development of new promising drugs”, underscores managing director of RUSNANO Evgeny Evdokimov.

“We are excited to have RUSNANO as an investor and partner in BiOptix, and I am confident they will accelerate our progress in building a successful enterprise” said Richard Whitcomb, President and CEO. “This investment allows us to tap into new markets and resources that were unavailable to us in the past.

BiOptix will expand the marketing of its instrumentation and establish a subsidiary in Russia (BiOptix Nanoprom LLC) to produce its disposable bionanosensors ? glass substrates covered with precision metallic and biofunctional nanofilms. In addition, the Company will create an R&D presence including partnering with researchers at Bionanophysica and other institutions in Russia to develop novel applications for its customers.

About BiOptix: BiOptix, Inc., headquartered in Boulder, Colorado, seeks to expand the power of labelfree technology with the ACCOLADE™, now available for purchase. The enabling technology for the BiOptix instrument was developed by Dr. John ‘Jan’ Hall, Professor Adjoint of Physics at the University of Colorado, who was awarded the Nobel Prize for Physics in 2005.

The ACCOLADE™ is a four?feature system designed for biomolecular kinetic analysis and targeted towards biopharmaceutical development and research markets. Built on BiOptix’ patented Surface Plasmon?Enhanced Interferometry technology, the ACCOLADE™ provides scientists an accurate and sensitive label?free system that is also easier to use, economical to operate, and accessible to laboratories with constrained budgets.